**Core Concept**
Parenteral Direct Thrombin Inhibitors (DTIs) are a class of anticoagulant medications that directly inhibit the activity of thrombin, a key enzyme in the coagulation cascade. They work by binding to the active site of thrombin, preventing its conversion of fibrinogen to fibrin and subsequent clot formation.

**Why the Correct Answer is Right**
The correct answer is a Parenteral Direct Thrombin Inhibitor that works by directly inhibiting thrombin activity, thereby preventing clot formation. This class of medications is typically used in acute settings, such as pulmonary embolism or myocardial infarction, to rapidly reverse thrombin-mediated clotting. The specific mechanism of action involves the binding of the drug to the active site of thrombin, which prevents its interaction with fibrinogen and subsequent clot formation.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect as it refers to a different class of anticoagulant medications. Heparin, a common anticoagulant, works by activating antithrombin III, which in turn inhibits thrombin activity. However, it is not a direct thrombin inhibitor.

**Option B:** This option is incorrect as it refers to a drug that inhibits Factor Xa, another key enzyme in the coagulation cascade. While Factor Xa inhibitors are effective anticoagulants, they do not directly inhibit thrombin activity.

**Option D:** This option is incorrect as it refers to a medication that inhibits platelet aggregation, rather than directly inhibiting thrombin activity.

**Clinical Pearl / High-Yield Fact**
In acute settings, Parenteral Direct Thrombin Inhibitors like the correct answer are often used as a bridge to long-term anticoagulation with oral medications. They are effective in rapidly reversing thrombin-mediated clotting and can be used in patients with renal impairment, making them a valuable option in certain clinical scenarios.

**Correct Answer: C. Argatroban. Argatroban is a parenteral direct thrombin inhibitor used to prevent and treat thrombosis in patients with heparin-induced thrombocytopenia.**